Urotensin II: A new player in vascular and myocardial disease?

Clinical Science

Volumn 104, Issue 1, 2003, Pages 65-67

  Krum, Henry ^a   Gilbert, Richard E ^b  

^a ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; GLUCOSE; NITRIC OXIDE; PROSTAGLANDIN DERIVATIVE; RENIN; UROTENSIN II; VASODILATOR AGENT;

DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DYSLIPIDEMIA; GLYCATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; KIDNEY CLEARANCE; MOLECULAR MIMICRY; MORBIDITY; MORTALITY; MYOCARDIAL DISEASE; NOTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASCULAR DISEASE; VASOCONSTRICTION;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS; ENDOTHELIUM, VASCULAR; HUMANS; UROTENSINS; VASOCONSTRICTION;

EID: 0037281865     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20020306     Document Type: Note

References (20)

1. Bern, H. A., Person, D., Larson, B. A. and Nishioka, R. S. (1995) Neurohormones from fish tails: the caudal neurosecretory system. I. 'Urophysiology' and the caudal neurosecretory system of fishes. Recent Prog. Hormone Res. 41, 533-552
2. Ames, R. S., Sarau, H. M., Chambers, J. K. et al. (1999) Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature (London) 401, 282-286
3. Maguire, J. J. and Davenport, A. P. (2002) Is urotensin-II the new endothelin? Br. J. Pharmacol. 137, 579-588
4. Hillier, C., Berry, C., Petrie, M. C. et al. (2001) Effects of urotensin II in human arteries and veins of varying caliber. Circulation 103, 1378-1381
5. Maguire, J. J., Kuc, R. E. and Davenport, A. P. (2000) Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br. J. Pharmacol. 131, 441-446
6. Stirrat, A., Gallagher, M., Douglas, S. A. et al. (2001) Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am. J. Physiol. Heart Circ. Physiol. 280, H925-H928
7. Bohm, F. and Pernow, J. (2002) Urotensin II evokes potent vasoconstriction in humans in vivo. Br. J. Pharmacol. 135, 25-27
8. Wilkinson, I. B., Affolter, J. T., de Haas, S. L. et al. (2002) High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc. Res. 53, 341-347
9. Tzanidis, A., Hannan, R., Thomas, W. et al. (2001) Increased expression of urotensin II and its receptor in an experimental model of left ventricular myocardial infarction in the rat: implications for cardiac remodelling. Eur. Heart J. 22 (Suppl.), Abtract 141
10. Douglas, S. A., Tayara, L., Ohlstein, E. H., Halawa, N. and Giaid, A. (2002) Congestive heart failure and expression of myocardial urotensin II. Lancet 359,1990-1997
11. Totsune, K., Takahashi, K., Arihara, Z., Sone, M., Ito, S. and Muramaki, O. (2003) Increased plasma urotensin II levels in patients with diabetes mellitus. Clin. Sci. 104, 1-5
12. Haynes, W. G. and Webb, D. J. (1998) Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens. 16, 1081-1098
13. Totsune, K., Takahashi, K., Arihara, Z. et al. (2001) Role of urotensin II in patients on dialysis. Lancet 358, 810-811
14. Richards, A. M., Nicholls, M. G., Lainchbury, J. G., Fisher, S. and Yandle, T. G. (2002) Plasma urotensin II in heart failure. Lancet 360, 545-546
15. Krüger, S., Graf, J., Janssens, U., Stickel, T., Kunz, D. and Hanrath, P. (2002) Human urotensin II and big endothelin in patients with chronic heart failure. Eur. Heart J. 23 (Suppl.), Abstract 86
16. Stangl, K., Bartsch, C., Richter, C., Romeyke, E., Baumann, G. and Dschietzig, T. (2001) Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure. Eur. Heart J. 22 (Suppl.), Abstract 39
17. Kuc, R. E., Maguire, J. J. and Davenport, A. P. (2001) Urotensin-II is a potent constrictor of human atherosclerotic coronary arteries with immunoreactive peptide localised to the atherosclerotic plaque. Br. J. Pharmacol. 134, 74
18. Ak, G., Buyukberber, S., Sevinc, A. et al. (2001) The relation between plasma endothelin-1 levels and metabolic control, risk factors, treatment modalities, and diabetic microangiopathy in patients with Type 2 diabetes mellitus. J. Diabetes Complications 15, 150-157
19. A-receptor antagonist. Circulation 96, 1965-1991
20. Behm, D. J., Herold, C. L., Ohlstein, E. H., Knight, S. D., Dhanak, D. and Douglas, S. A. (2002) Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist. Br. J. Pharmacol. 137, 449-458